Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis.
NCT ID: NCT03052348
Last Updated: 2017-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
78 participants
INTERVENTIONAL
2017-11-01
2018-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Fusidic Acid (FA) cream is a topical antibiotic widely used in the treatment of skin and soft tissue infections and infected atopic dermatitis. However in recent years, the emergence of drug-resistant organisms, e.g. Methicillin- resistant Staphylococcus aureus (MRSA) has led to scrutiny of antibiotic use. Prolonged use of topical FA has been linked with emergence of FA-resistant Staphylococcus aureus (FRSA) . Fusidic acid is a natural antibiotic, extracted from cultures of Fusidium coccineum, which has a powerful antibacterial action. Topical use of Fusidic acid is fully in line with therapeutic strategies that recommend the use of an antibiotic with the narrowest activity spectrum to minimize the risk of resistance. In AD with infected lesions, combined treatment with antibiotic and steroid demonstrates greater efficacy over the use of steroid.
Trial Design: A three-center, double blind, randomized ,phase II , parallel group, efficacy trial.
Type of Intervention: A triple compounded cream containing a topical antibiotic , topical steroid and moisturizer.
Type of control: Active control containing a double compounded cream comprising a topical steroid and moisturizer .
Study population and Setting: A sample of 78 subjects will be recruited from Red Cross Children's Hospital , Nelson Mandela Academic Hospital and King Edward Hospital Estimated duration of trial: 12 months. Duration of participation: Each subject will participate in the trial for a maximum of 140 days.
Primary endpoint: reduction in SCORAD scores; frequency of clinical flares for AD and improvement in the quality of life at 140 days.
The benefit of this trial is that it provides a simple and effective approach to the management of atopic eczema.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group R
Polyethylene glycol hexadecyl ether \& betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
Group A
Fusidic acid \& Polyethylene glycol hexadecyl ether,\& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have have AD as defined by the UK Working Party Criteria
* Participants can be female or male, older than 2 years but younger than 10 years (up to their 10th birthday)
* Participants must not be on systemic antibiotics treatment at recruitment
* Participants must have a baseline SCORAD score of 50 or above (severe AD)
* Participants must be eligible for second line treatment agents for AD (systemic or photo therapy)
Exclusion Criteria
* Participants must not be younger than 2 years or over 10 years in age.
* Participants must not be using g bleach baths as a staphylococcus eradication measure at the time of enrollment,
* Participants must not have mild-moderate AD (SCORAD\< 50)
* Participants must not be immune-compromised with AD
* Participants must not be on photo therapy for AD
* Participants must not be using wet wrap therapy for AD
2 Years
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Red Cross War Memorial Childrens Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Carol Hlela
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Carol Hlela, MBCHB
Role: PRINCIPAL_INVESTIGATOR
Red Cross Children's War Memorial Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nelson Mandela Academic Hospital
Mthatha, Eastern Cape, South Africa
King Edward Hospital
Durban, KwaZulu-Natal, South Africa
Red Cross War Memorial Children's Hospital
Cape Town, Western Cape, South Africa
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, Chamlin SL, Cohen DE, Cordoro KM, Davis DM, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Simpson EL, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Eichenfield LF. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014 Dec;71(6):1218-33. doi: 10.1016/j.jaad.2014.08.038. Epub 2014 Sep 26.
Cardona ID, Cho SH, Leung DY. Role of bacterial superantigens in atopic dermatitis : implications for future therapeutic strategies. Am J Clin Dermatol. 2006;7(5):273-9. doi: 10.2165/00128071-200607050-00001.
Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009 May;123(5):e808-14. doi: 10.1542/peds.2008-2217.
Langan SM, Thomas KS, Williams HC. What is meant by a "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006 Sep;142(9):1190-6. doi: 10.1001/archderm.142.9.1190.
Totte JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016 Oct;175(4):687-95. doi: 10.1111/bjd.14566. Epub 2016 Jul 5.
Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Munoz-Planillo R, Hasegawa M, Villaruz AE, Cheung GY, McGavin MJ, Travers JB, Otto M, Inohara N, Nunez G. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature. 2013 Nov 21;503(7476):397-401. doi: 10.1038/nature12655. Epub 2013 Oct 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RedCrossWMCH
Identifier Type: -
Identifier Source: org_study_id